Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Boussios S, Sadauskaite A, Kanellos FS, et al. Neoadjuvant, HIPEC and maintenance treatment in ovarian and peritoneal serous cancer: current status. Gynecol Pelvic Med. 2020;3:19.
   Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Bamias A, Gibbs E, Khoon Lee C, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol. 2017;28(8):1842–1848.
   PubMed Web of Science ®Google Scholar
• O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60:547–560.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Coleman R, Oza A, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428.
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402.
   PubMed Web of Science ®Google Scholar
• Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) Polymerase Inhibitors: talazoparib in Ovarian Cancer and Beyond. Drugs R&D. 2020;20(2):55–73.
   PubMed Web of Science ®Google Scholar
• Pietragalla A, Ciccarone F, Nero C, et al., Integration of PARP-inhibitors in ovarian cancer therapy. Explor Target Anti-tumor Ther. 2020;1(3):171–182.
   Google Scholar
• Topalian SL, Hodi SF, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Xu ZP, et al. PD-L1 distribution and perspective for cancer immunotherapy— blockade, knockdown, or inhibition. Front Immunol. 2019;10. DOI:10.3389/fimmu.2019.02022
   Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008 Aug;224(1):166–182.
   PubMedGoogle Scholar
• Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–116.
   PubMed Web of Science ®Google Scholar
• Maus MV, Fraietta JA, Levine BL, et al. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014;32:189–225.
   PubMed Web of Science ®Google Scholar
• Yi M, Qin S, Zhao W, et al. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol. 2018;7(1):28.
   PubMedGoogle Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Colombo N, Oza M, et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial. 2020. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. LBA 25, Scientific Plenary.
   Google Scholar
• Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Gyn Oncol. 2019;154(Supp 1):21–22.
   Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019 Jul;30(7):1080–1087.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Shapira R, Santin A, et al. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. J Clin Oncol. 2020 May;38(15_suppl):6005.
   Google Scholar
• Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02440425?term=02440425&draw=2&rank=1
   Google Scholar
• Zamarin D, Burger RA, Sill MW, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol. 2020;38(16):1814–1823.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study. J Clin Oncol. 2013 Apr;31(12):1554–1561.
   PubMed Web of Science ®Google Scholar
• Brewer M, Angioli R, Scambia G, et al. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecol Oncol. 2020 Mar;156(3):523–529.
   PubMed Web of Science ®Google Scholar
• Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00652899?term=NCT00652899&draw=2&rank=1
   Google Scholar
• A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL). Available from:  https://www.clinicaltrials.gov/ct2/show/NCT03398655
   Google Scholar
• Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 2018;78(24):6717–6725.
   PubMed Web of Science ®Google Scholar
• Gao P, Ascano M, Wu Y, et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell. 2013 May;153(5):1094–1107.
   PubMed Web of Science ®Google Scholar
• Li A, Yi M, Qin S. et al. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019;12(1):1–12.
   PubMedGoogle Scholar
• Simmons DP, Wearsch PA, Canaday DH, et al. Type I IFN Drives a Distinctive Dendritic Cell Maturation Phenotype That Allows Continued Class II MHC Synthesis and Antigen Processing. J Immunol. 2012 Apr;188(7):3116–3126.
   PubMed Web of Science ®Google Scholar
• Guillot B, Portalès P, Du Thanh A, et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-α treatment. Br J Dermatol. 2005 Apr;152(4):690–696.
   PubMed Web of Science ®Google Scholar
• Bacher N, Raker V, Hofmann C, et al. Interferon-a suppresses cAMP to disarm human regulatory T cells. Cancer Res. 2013 Sep;73(18):5647–5656.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res. 2015 Nov;3(11):1257–1268.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Combined strategies with poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A literature review. Diagnostics. 2019;9(3):87.
   Web of Science ®Google Scholar
• Drew Y, Kaufman B, Banerjee S, et al. Phase II study of olaparib + durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). 2019 European Society Medical Oncology Congress; Abstract 1190PD.
   Google Scholar
• Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019;5(8):1141–1149.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Meniawy T, Markman B, et al. A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. J Clin Oncol. 2017;35(15):3013.
   Google Scholar
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03737643
   Google Scholar
• Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03740165.
   Google Scholar
• A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03602859
   Google Scholar
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA). Available from: https://clinicaltrials.gov/ct2/show/NCT03522246
   Google Scholar
• ATALANTE: atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (ATALANTE). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02891824
   Google Scholar
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02839707
   Google Scholar
• Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04034927
   Google Scholar
• Moore KN, Pignata S. Trials in progress: iMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV o. Int J Gynecol Cancer. 2019;29(2):430–433.
   Web of Science ®Google Scholar
• Gao X, McDermott DF. Combinations of bevacizumab with immune checkpoint inhibitors in renal cell carcinoma. Cancer J. 2018;24(4):171–179.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen Y, Li F, et al. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. Front Immunol. 2019 Apr;10(APR):867.
   PubMedGoogle Scholar
• Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer. Available from https://www.roche.com/dam/jcr:d1d8a569-22a5-4a49-b297-d48805b0807f/en/13072020-media-release-tecentriq.pdf
   Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3 — potential mechanisms of action. Nat Rev Immunol. 2015;15:45–56.
   PubMed Web of Science ®Google Scholar
• Roane BM, Arend RC, Birrer MJ. Review: targeting the transforming growth factor-beta pathway in ovarian cancer. Cancers. 2019;11(4):668.
   Google Scholar
• Kim JY, Cho CH, Song HS. Targeted therapy of ovarian cancer including immune check point inhibitor. Korean J Intern Med. 2017;32:798–804.
   PubMed Web of Science ®Google Scholar